The California Department of Public Health (CDPH) has issued a Health Alert to remind providers that once an individual is diagnosed with COVID-19, early treatment with COVID-19-specific agents is the only existing strategy to markedly decrease the risk of serious illness. CDPH states that there is an ample supply of COVID-19 therapeutics, however they have been underused in many vulnerable populations. Paxlovid (ritonavir-boosted nirmatrelvir) and IV remdesivir are the preferred treatments for nonhospitalized patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease.
